Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsAngela Cappiello, MD, PhD
Assistant Clinical ProfessorDownloadHi-Res Photo
About
Copy Link
Biography
Angela Cappiello, M.D., Ph.D., practices general psychiatry, psychotherapy and psychoanalysis. She is a Diplomate of the American Board of Psychiatry and Neurology, and a Fellow of the American Board of Psychoanalysis. She is on the faculty, and is also a Training and Supervising Analyst at the Western New England Institute for Psychoanalysis.
Last Updated on November 21, 2022.
Appointments
Education & Training
- PhD
- La Sapienza University, Rome Italy
- MD
- La Sapienza University, Rome Italy
Research
Copy Link
Research at a Glance
Yale Co-Authors
Frequent collaborators of Angela Cappiello's published research.
Publications Timeline
A big-picture view of Angela Cappiello's research output by year.
Dan Oren, MD, BS
John Krystal, MD
Kathryn Czarkowski, MA
Ralitza Gueorguieva, PhD
Gerard Sanacora, PhD, MD
Lawrence Staib, PhD
15Publications
4,588Citations
Publications
2007
The resistance to depressive relapse in menopausal women undergoing tryptophan depletion: preliminary findings
Epperson CN, Amin Z, Naftolin F, Cappiello A, Czarkowski KA, Stiklus S, Anderson GM, Krystal JH. The resistance to depressive relapse in menopausal women undergoing tryptophan depletion: preliminary findings. Journal Of Psychopharmacology 2007, 21: 414-420. PMID: 16891341, DOI: 10.1177/0269881106067330.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsMenopausal womenTryptophan depletionSelective serotonin reuptake inhibitor fluoxetineAcute tryptophan depletion paradigmSerotonin reuptake inhibitor fluoxetineTryptophan depletion paradigmPathogenesis of depressionReuptake inhibitor fluoxetineMajor depressive episodeAcute tryptophan depletionRelapse of depressionWorsening of moodWeeks of recoveryActive tryptophan depletionWechsler Memory ScaleAssessment of moodDepressive episodeRisk factorsDepressive relapseMajor depressionSignificant worseningNeuroendocrine functionVerbal memorySerotonergic contributionMemory Scale
2006
Estradiol and Tryptophan Depletion Interact to Modulate Cognition in Menopausal Women
Amin Z, Gueorguieva R, Cappiello A, Czarkowski KA, Stiklus S, Anderson GM, Naftolin F, Epperson CN. Estradiol and Tryptophan Depletion Interact to Modulate Cognition in Menopausal Women. Neuropsychopharmacology 2006, 31: 2489-2497. PMID: 16760926, DOI: 10.1038/sj.npp.1301114.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsVerbal memory performanceVerbal memory scoresPositive mood effectsVerbal memoryVisuospatial learningMemory performanceVerbal fluencyMemory scoresMood effectsEstrogen treatmentSubjects designCognitionTryptophan depletionMenopausal womenLittle researchSignificant interactionHealthy menopausal womenLast menstrual periodNonreproductive behaviorsInteraction of estrogenActive TrPsOvarian steroidsMenstrual periodProtective effectFluency
2004
Addition of the α2-Antagonist Yohimbine to Fluoxetine: Effects on Rate of Antidepressant Response
Sanacora G, Berman RM, Cappiello A, Oren DA, Kugaya A, Liu N, Gueorguieva R, Fasula D, Charney DS. Addition of the α2-Antagonist Yohimbine to Fluoxetine: Effects on Rate of Antidepressant Response. Neuropsychopharmacology 2004, 29: 1166-1171. PMID: 15010697, DOI: 10.1038/sj.npp.1300418.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHamilton depression scale ratingsΑ2-antagonist yohimbineAntidepressant responseClinical Global Impression ratingsBlood pressure changesPercentage of respondersLog-rank testGlobal Impression ratingsMajor depressive disorderMore rapid onsetP subjectsDSM-IV diagnosisSSRI agentsTitrated doseYohimbine doseAntidepressant actionAntidepressant medicationCGI scaleNoradrenergic toneMonoaminergic neurotransmissionΑ2-adrenoceptorsDepressive disorderTreatment periodOutcome measuresSCID interview
2000
268. Simultaneous catecholamine and indoleamine depletion in unmedicated depressed subjects
Berman R, Sanacora G, Narasimhan M, Oren D, Cappiello A, Charney D. 268. Simultaneous catecholamine and indoleamine depletion in unmedicated depressed subjects. Biological Psychiatry 2000, 47: s81. DOI: 10.1016/s0006-3223(00)00532-1.Peer-Reviewed Original ResearchCitationsAttenuation of the Neuropsychiatric Effects of Ketamine With Lamotrigine: Support for Hyperglutamatergic Effects of N-methyl-D-aspartate Receptor Antagonists
Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, Krystal JH. Attenuation of the Neuropsychiatric Effects of Ketamine With Lamotrigine: Support for Hyperglutamatergic Effects of N-methyl-D-aspartate Receptor Antagonists. JAMA Psychiatry 2000, 57: 270-276. PMID: 10711913, DOI: 10.1001/archpsyc.57.3.270.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAdultAffectBrief Psychiatric Rating ScaleCognition DisordersDouble-Blind MethodExcitatory Amino Acid AntagonistsFemaleGlutamatesHumansKetamineLamotrigineMaleMental DisordersPerceptual DisordersPlacebosPsychiatric Status Rating ScalesReceptors, N-Methyl-D-AspartateSchizophreniaSchizophrenic PsychologyTriazinesVerbal LearningConceptsN-methyl-D-aspartate receptor antagonistNMDA receptor dysfunctionReceptor antagonistNeuropsychiatric effectsGlutamate releaseReceptor dysfunctionSymptom subscalesPlacebo 2 hoursClinician-Administered Dissociative States ScaleAdministration of lamotrigineAdministration of ketamineDouble-blind conditionsNMDA receptor antagonistMood-elevating effectsPositive symptom subscaleBrief Psychiatric RatingNovel therapeutic agentsNegative symptom subscaleHopkins Verbal Learning TestVerbal Learning TestKetamine effectsPsychiatric illnessHealthy subjectsPathophysiologic processesPreclinical studiesAntidepressant effects of ketamine in depressed patients
Berman R, Cappiello A, Anand A, Oren D, Heninger G, Charney D, Krystal J. Antidepressant effects of ketamine in depressed patients. Biological Psychiatry 2000, 47: 351-354. PMID: 10686270, DOI: 10.1016/s0006-3223(99)00230-9.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAdultAntidepressive AgentsDepressive Disorder, MajorDose-Response Relationship, DrugDouble-Blind MethodExcitatory Amino Acid AntagonistsFemaleGlutamic AcidHumansInjections, IntravenousKetamineMaleMiddle AgedPsychiatric Status Rating ScalesReceptors, N-Methyl-D-AspartateSeverity of Illness IndexConceptsMajor depressionN-methyl-D-aspartate receptor antagonistBrain glutamate systemDouble-blind trialDouble-blind conditionsTreatment of depressionMechanism of actionPlacebo infusionAntidepressant effectsIntravenous treatmentSingle doseReceptor antagonistDepressed patientsGlutamate systemDepressive symptomsPreclinical researchKetamine hydrochlorideDepressionPotential roleTest dayTreatment effectsPatientsKetamineSaline solutionTreatmentSPECT [I-123]iomazenil measurement of the benzodiazepine receptor in panic disorder
Bremner J, Innis R, White T, Fujita M, Silbersweig D, Goddard A, Staib L, Stern E, Cappiello A, Woods S, Baldwin R, Charney D. SPECT [I-123]iomazenil measurement of the benzodiazepine receptor in panic disorder. Biological Psychiatry 2000, 47: 96-106. PMID: 10664825, DOI: 10.1016/s0006-3223(99)00188-2.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsBenzodiazepine receptor bindingBenzodiazepine receptor functionPanic disorder patientsBenzodiazepine receptorsPanic disorderReceptor bindingDisorder patientsPanic attacksReceptor functionPrefrontal cortexSingle photon emissionStatistical parametric mappingGABAergic transmissionHealthy controlsFrontal cortexLeft hippocampusAnimal modelsComparison subjectsPatientsChronic stressPanic anxietyTomography imagingParametric mappingCortexSpecific decrease
1999
Transient Depressive Relapse Induced by Catecholamine Depletion: Potential Phenotypic Vulnerability Marker?
Berman RM, Narasimhan M, Miller HL, Anand A, Cappiello A, Oren DA, Heninger GR, Charney DS. Transient Depressive Relapse Induced by Catecholamine Depletion: Potential Phenotypic Vulnerability Marker? JAMA Psychiatry 1999, 56: 395-403. PMID: 10232292, DOI: 10.1001/archpsyc.56.5.395.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCatecholamine depletionMedication-free subjectsMajor depressionHamilton Depression Rating Scale scoresDepression Rating Scale scoresBaseline plasma cortisol levelsDepressive reactionsSignificant depressive symptomsRating Scale scoresHistory of depressionState-related alterationsPlasma cortisol levelsCatecholamine functionAlpha-methylparatyrosineRelapse criteriaBlood samplesDepressive symptomsCortisol levelsCrossover designScale scoreDepressed subjectsReliable markerTransient increaseVulnerability markerAnxiety symptomsThe use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial
Berman R, Anand A, Cappiello A, Miller H, Hu X, Oren D, Charney D. The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial. Biological Psychiatry 1999, 45: 1170-1177. PMID: 10331109, DOI: 10.1016/s0006-3223(98)00383-7.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPlacebo groupClinical responseMore weeksDrug-free outpatientsEfficacy of pindololPartial remission rateUse of pindololPlacebo-controlled trialDouble-blind mannerMajor depressive episodeSingle-blind mannerPindolol groupPindolol treatmentPartial remissionRemission rateBlood pressureReuptake inhibitorsStudy endPatient populationDepressive episodeDepressed patientsMajor depressionRecurrent depressionSide effectsControl groupEffect of catecholamine depletion on lithium-induced long-term remission of bipolar disorder
Anand A, Darnell A, Miller H, Berman R, Cappiello A, Oren D, Woods S, Charney D. Effect of catecholamine depletion on lithium-induced long-term remission of bipolar disorder. Biological Psychiatry 1999, 45: 972-978. PMID: 10386179, DOI: 10.1016/s0006-3223(98)00293-5.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsLong-term remissionBipolar disorderCatecholamine depletionLithium therapyHypomanic symptomsLong-term lithium therapyRandomized double-blind mannerDSM-IV bipolar disorderDouble-blind mannerMechanism of preventionTransient relapseManic relapsePlacebo administrationSerum levelsCatecholamine systemsHomovanillic acidRemissionRelapseDisordersTherapyTest sessionsSymptomsSubjectsSignificant changesMood indices